Atomwise Atomnet News Today

Discovery of a novel cardiac-specific myosin modulator.

/PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Artificial Intelligence in Precision Medicine Market Share, Size,...

Published: Dec 21, 2020 Dec. 21, 2020 21:37 UTC Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informas Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, today unveiled its grow...

Press release content from Business Wire. The AP news staff was not involved in its creation. Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority December 18, 2020 GMT SAN FRANCISCO & NESS ZIONA, Israel--(BUSINESS WIRE)--Dec 18, 2020-- Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotec...

(1) A2i Therapeutics secures seed funding from FutuRx and its investors Johnson Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority to develop novel small molecule immuno-oncology agents. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic tech...